Reading MIRA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track MIRA free→Reading MIRA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track MIRA free→QuarterlyIQ Insights · MIRA
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Andriy Mushak as the Fractional Chief Financial Officer Effective June 6, 2026, Alan Weichselbaum will be no longer serving as the Chief Financial Officer of Mira Pharmaceuticals, Inc. (the “Company”). Mr. Weichselbaum’s departure was not the result of any disagreement with the Company on any matter relating to the Company’s operatio…
Entry into a Material Definitive Agreement. On June 3, 2026, MIRA Pharmaceuticals, Inc. (the “Company”) entered into an Amended and Restated Exclusive License Agreement (the “License Agreement”) with MIRALOGX LLC (“Miralogx”). Pursuant to the License Agreement, Miralogx granted the Company worldwide exclusive rights under certain intellectual property relating to the Company’s MIRA-55 and SKNY-1 development programs. The License Agreement provides the Company with worldwide rights to develop,…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.